July 2, 2024

Ultrasound-Activated PROTAC Prodrugs Overcome Immunosuppression to Actuate Efficient Deep-Tissue Sono-Immunotherapy in Orthotopic Pancreatic Tumor Mouse Models

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

The degradation of oncoproteins mediated by proteolysis-targeting chimera (PROTAC) has emerged as a potent strategy in cancer therapy. However, the clinical application of PROTACs is hampered by challenges such as poor water solubility and off-target adverse effects. Herein, we present an ultrasound (US)-activatable PROTAC prodrug termed NP

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Liu et al. (Tue,) studied this question.

synapsesocial.com/papers/68e61927b6db6435875ac325 https://doi.org/https://doi.org/10.1021/acs.nanolett.4c02287

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cancer Immunotherapy: Reprogramming the Tumor Microenvironment through Second‐Near‐Infrared‐Window Photothermal Genome Editing of <i>PD‐L1</i> Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy (Adv. Mater. 12/2021)2021 · 2 citations
2Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation2001 · 2,475 citations
3The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors2021 · 493 citations
4Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy2023 · 129 citations
5Augmenting Immunogenic Cell Death and Alleviating Myeloid‐Derived Suppressor Cells by Sono‐Activatable Semiconducting Polymer Nanopartners for Immunotherapy2023 · 95 citations

Preguntar a la IA

Me gusta

Guardar